FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088606503> ?p ?o ?g. }

• W2088606503 endingPage "460" @default.
• W2088606503 startingPage "447" @default.
• W2088606503 abstract "The aim of this study was to assess the efficacy and safety of the once-daily atomoxetine compared with placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Taiwan.The study sample included 106 patients aged 6-16 years who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria of ADHD randomly assigned to atomoxetine once daily (n = 72) and placebo once daily (n = 34) in a double-blind, 6-week treatment study. The primary efficacy measure was the total score of the ADHD Rating Scale-IV Parents Version: Investigator Administered and Scored. The secondary efficacy measures included the Clinical Global Impressions--ADHD--Severity and Chinese Conner's Parent and Teacher Rating Scale--Revised: Short Form. Data were analyzed on an intent-to-treat basis and a last-observation-carried-forward approach.The two treatment groups did not differ in demographics and baseline measures. Compared to the placebo group, the atomoxetine group showed significantly greater reductions in ADHD-related symptoms according to the ratings of investigators, parents, and teachers. The treatment effect size of the primary efficacy measure was 0.70 at the end of study. Adverse events reported significantly more frequently with atomoxetine were decreased appetite (36.1%) and nausea (16.6%). No drug-related serious adverse event was observed.Once-daily atomoxetine is an effective, well-tolerable, and safe treatment for children and adolescents with ADHD in Taiwan." @default.
• W2088606503 created "2016-06-24" @default.
• W2088606503 creator A5011518410 @default.
• W2088606503 creator A5028332065 @default.
• W2088606503 creator A5064077087 @default.
• W2088606503 creator A5068339113 @default.
• W2088606503 creator A5069235025 @default.
• W2088606503 creator A5078469078 @default.
• W2088606503 creator A5081693966 @default.
• W2088606503 creator A5087181752 @default.
• W2088606503 creator A5087186289 @default.
• W2088606503 date "2007-08-01" @default.
• W2088606503 modified "2023-10-13" @default.
• W2088606503 title "A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder" @default.
• W2088606503 cites W110926174 @default.
• W2088606503 cites W1514128735 @default.
• W2088606503 cites W1564761171 @default.
• W2088606503 cites W1973440222 @default.
• W2088606503 cites W1980333466 @default.
• W2088606503 cites W2006058627 @default.
• W2088606503 cites W2016483680 @default.
• W2088606503 cites W2020927600 @default.
• W2088606503 cites W2030460171 @default.
• W2088606503 cites W2044253418 @default.
• W2088606503 cites W2083338868 @default.
• W2088606503 cites W2112484680 @default.
• W2088606503 cites W2117062136 @default.
• W2088606503 cites W2117095140 @default.
• W2088606503 cites W2120948822 @default.
• W2088606503 cites W2122518346 @default.
• W2088606503 cites W2123910896 @default.
• W2088606503 cites W2123980944 @default.
• W2088606503 cites W2140513029 @default.
• W2088606503 cites W2144962889 @default.
• W2088606503 cites W2147033404 @default.
• W2088606503 cites W2160344121 @default.
• W2088606503 cites W2518157807 @default.
• W2088606503 cites W2601578636 @default.
• W2088606503 cites W2809218088 @default.
• W2088606503 cites W4247742608 @default.
• W2088606503 cites W59913820 @default.
• W2088606503 cites W71528383 @default.
• W2088606503 doi "https://doi.org/10.1089/cap.2006.0091" @default.
• W2088606503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17822340" @default.
• W2088606503 hasPublicationYear "2007" @default.
• W2088606503 type Work @default.
• W2088606503 sameAs 2088606503 @default.
• W2088606503 citedByCount "58" @default.
• W2088606503 countsByYear W20886065032012 @default.
• W2088606503 countsByYear W20886065032013 @default.
• W2088606503 countsByYear W20886065032014 @default.
• W2088606503 countsByYear W20886065032015 @default.
• W2088606503 countsByYear W20886065032016 @default.
• W2088606503 countsByYear W20886065032017 @default.
• W2088606503 countsByYear W20886065032018 @default.
• W2088606503 countsByYear W20886065032020 @default.
• W2088606503 countsByYear W20886065032021 @default.
• W2088606503 countsByYear W20886065032022 @default.
• W2088606503 countsByYear W20886065032023 @default.
• W2088606503 crossrefType "journal-article" @default.
• W2088606503 hasAuthorship W2088606503A5011518410 @default.
• W2088606503 hasAuthorship W2088606503A5028332065 @default.
• W2088606503 hasAuthorship W2088606503A5064077087 @default.
• W2088606503 hasAuthorship W2088606503A5068339113 @default.
• W2088606503 hasAuthorship W2088606503A5069235025 @default.
• W2088606503 hasAuthorship W2088606503A5078469078 @default.
• W2088606503 hasAuthorship W2088606503A5081693966 @default.
• W2088606503 hasAuthorship W2088606503A5087181752 @default.
• W2088606503 hasAuthorship W2088606503A5087186289 @default.
• W2088606503 hasConcept C118552586 @default.
• W2088606503 hasConcept C126322002 @default.
• W2088606503 hasConcept C138496976 @default.
• W2088606503 hasConcept C142724271 @default.
• W2088606503 hasConcept C15744967 @default.
• W2088606503 hasConcept C168563851 @default.
• W2088606503 hasConcept C187212893 @default.
• W2088606503 hasConcept C197934379 @default.
• W2088606503 hasConcept C204787440 @default.
• W2088606503 hasConcept C27081682 @default.
• W2088606503 hasConcept C2777112843 @default.
• W2088606503 hasConcept C2778781522 @default.
• W2088606503 hasConcept C2780580376 @default.
• W2088606503 hasConcept C2780783007 @default.
• W2088606503 hasConcept C2909253567 @default.
• W2088606503 hasConcept C535046627 @default.
• W2088606503 hasConcept C71924100 @default.
• W2088606503 hasConcept C83849319 @default.
• W2088606503 hasConceptScore W2088606503C118552586 @default.
• W2088606503 hasConceptScore W2088606503C126322002 @default.
• W2088606503 hasConceptScore W2088606503C138496976 @default.
• W2088606503 hasConceptScore W2088606503C142724271 @default.
• W2088606503 hasConceptScore W2088606503C15744967 @default.
• W2088606503 hasConceptScore W2088606503C168563851 @default.
• W2088606503 hasConceptScore W2088606503C187212893 @default.
• W2088606503 hasConceptScore W2088606503C197934379 @default.
• W2088606503 hasConceptScore W2088606503C204787440 @default.
• W2088606503 hasConceptScore W2088606503C27081682 @default.
• W2088606503 hasConceptScore W2088606503C2777112843 @default.

• next